A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML

Pediatric AML is traditionally treated with chemotherapy and stem cell transplant but some subsets of patients have a poor response to therapy. Here, the authors perform a high throughput screen and identify several FDA approved drugs that might be useful in treating this disease.

Saved in:

Bibliographic Details
Main Authors:	Christina D. Drenberg, Anang Shelat, Jinjun Dang, Anitria Cotton, Shelley J. Orwick, Mengyu Li, Jae Yoon Jeon, Qiang Fu, Daelynn R. Buelow, Marissa Pioso, Shuiying Hu, Hiroto Inaba, Raul C. Ribeiro, Jeffrey E. Rubnitz, Tanja A. Gruber, R. Kiplin Guy, Sharyn D. Baker
Format:	article
Language:	EN
Published:	Nature Portfolio 2019
Subjects:	Science Q
Online Access:	https://doaj.org/article/f909cbdab341455d9f702b6081a46e6f
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML

Similar Items